Clinical Trial Update: Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluated combination chemotherapy with PSC-833 (valspodar) followed by interleukin-2 in patients with acute myeloid leukemia; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Interleukin-2 (interleukin-2)
• PSC-833 (valspodar) (valspodar)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED